Research & Development Pipeline

RS Oncology’s development pipeline was initiated in early 2022 with the phase 1/2 MITOPE clinical trial

RSO-021

Local intrapleural administration via a catheter

Malignant Pleural Mesothelioma

Malignant Cancers with Pleural Effusion

Breast

Ovarian

NSCLC

Intraperitoneal Administration

Solid Tumors

TBD

Single Agent Meso with MPE 2nd or beyond

Single Agent all solid tumors with MPE 2nd or beyond

RSO-021 window of opportunity meso

RSO-021 + Paclitaxel in lung with MPE in 2nd or beyond

Systemic Treatment

Solid Tumors

Liquid Tumors

TBD

Topical Therapy

Melanoma
TBD